What topics does this cannabis study cover?

This study covers research on: Cancer.

Where was this research published?

Published in Cell & bioscience on May 28, 2026.

CBD breakthrough: Could boost breast cancer drug effectiveness

Q: What did this research study find?

This groundbreaking research demonstrates that **CBD significantly enhances the effectiveness of tamoxifen**, a widely-used breast cancer treatment. The study found that combining *CBD* with tamoxifen **dramatically increased cancer cell death** in laboratory models of ER-positive breast cancer—the

Cannabidiol enhances tamoxifen efficacy via CREB-mediated suppression of ERα signaling in ER-positive breast cancer cells.

Cell & bioscience • May 28, 2026 • Moderately Relevant

🤖

AI Summary

This groundbreaking research demonstrates that CBD significantly enhances the effectiveness of tamoxifen, a widely-used breast cancer treatment. The study found that combining CBD with tamoxifen dramatically increased cancer cell death in laboratory models of ER-positive breast cancer—the most common form of breast cancer in women. Importantly, this combination worked in cells that had become resistant to tamoxifen alone, suggesting CBD could help patients whose cancers have stopped responding to standard hormone therapy.

The key to this improvement lies in how CBD works at the molecular level. Researchers discovered that CBD suppresses a cellular signaling pathway (cAMP/CREB) that normally helps cancer cells survive and grow. By blocking this pathway, CBD forces cancer cells to reduce their production of estrogen receptors—the very targets that tamoxifen attacks. This creates a two-pronged attack: tamoxifen has more receptors to bind to, and the cancer cells have fewer defense mechanisms. When tested in living mice, the combined treatment significantly slowed tumor growth and reduced cancer cell survival markers in tumor tissues.

These findings could have substantial implications for breast cancer patients, particularly those experiencing tamoxifen resistance—a condition affecting many patients on long-term hormone therapy. While these are early laboratory and animal studies that require further clinical validation, the results suggest CBD may serve as a novel "adjuvant" agent to restore treatment sensitivity and improve outcomes. Future clinical trials will be essential to confirm whether this laboratory promise translates to real benefits for human patients.

📄 Original Abstract

Estrogen receptor alpha (ERα) plays a crucial role in the proliferation and survival of ER-positive breast cancer cells, and tamoxifen (TAM) remains the mainstay of endocrine therapy. However, acquired resistance to TAM remains a major clinical challenge. Despite advances in molecular profiling and targeted therapies, the mechanisms underlying TAM resistance remain incompletely understood. Emerging evidence suggest that dysregulation of intracellular signaling pathways, including the cAMP/CREB axis, may contribute to endocrine therapy failure. We investigated the effects of cannabidiol (CBD) on TAM sensitivity and elucidated its underlying mechanisms in ER-positive breast cancer models. Human breast cancer cell lines (MCF7 and T47D) were treated with CBD, TAM or their combination. Apoptosis, proliferation, and protein expression were evaluated by flow cytometry, western blotting, and immunofluorescence. In vivo efficacy was examined in xenograft models. CBD significantly enhanced TAM-induced cell death and apoptosis in ER-positive breast cancer cell. Mechanistically, CBD suppressed the cAMP/CREB signaling pathway, leading to downregulation of ERα and its target genes (TFF1, GREB1, CCND1). Co-immunoprecipitation revealed that CBD inhibited the interaction between phosphorylated CREB and CBP, resulting in transcriptional suppression of ERα. In vivo, combined treatment with CBD and TAM synergistically inhibited tumor growth and reduced ERα and p-CREB expression levels in tumor tissues. Our findings demonstrate that CBD restores TAM sensitivity through CREB-mediated downregulation of ERα signaling in ER-positive breast cancer. This study suggests the potential application of CBD as a novel adjuvant agent to overcome TAM resistance and improve therapeutic outcomes in patients with ER-positive breast cancer.

Paper Type

📄 Research

Publication

Journal: Cell & bioscience
Published: May 28, 2026
PMID: 42210419
DOI: 10.1186/s13578-026-01588-x

Authors (10)

Bu Gyeom Kim Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, 08308, Seoul, Republic of Korea.
Okhyeon Kim Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, 08308, Seoul, Republic of Korea.
Do-Yeon Lee Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, 08308, Seoul, Republic of Korea.
Bo Ram Kim Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, 08308, Seoul, Republic of Korea.
Dae Yeong Kim Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, 08308, Seoul, Republic of Korea.
+5 more authors